Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 9:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 781 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Angiogram Clear all
Completed Early Phase 1 Interventional

A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer

NCT03143270
View directory record Official record
Conditions
Liver Cancer
Interventions
Drug Eluting Bead Transarterial Chemoembolization, Nivolumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
9
States / cities
St Louis, Missouri • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 22, 2026, 9:32 PM EDT
Active, not recruiting Phase 2 Interventional

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

NCT05554328
View directory record Official record
Conditions
Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Computed Tomography, Echocardiography Test, Multigated Acquisition Scan, Olaparib, Selumetinib Sulfate
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
292
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 229 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 22, 2026, 9:32 PM EDT
Completed No phase listed Observational

Comparative Renal Function of Young (18-45 Years) and Ageing (55 Years and Above) Kidney Donors

NCT00846729
View directory record Official record
Conditions
Kidney Diseases
Interventions
CT angiogram of the remaining kidney., Kidney Function study using Iothalamate & PAH as clearance markers
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Oct 22, 2026, 9:32 PM EDT
Recruiting Phase 1 Interventional

Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas

NCT06964737
View directory record Official record
Conditions
Recurrent Malignant Glioma, Recurrent WHO Grade 3 Glioma, Recurrent WHO Grade 4 Glioma, WHO Grade 2 Glioma, WHO Grade 3 Glioma, WHO Grade 4 Glioma
Interventions
Anti-GARP Chimeric Antigen Receptor-T Cells, Biospecimen Collection, Chest Radiography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pheresis, Surgical Procedure
Biological · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 22, 2026, 9:32 PM EDT
Recruiting Phase 1 Interventional

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

NCT06058663
View directory record Official record
Conditions
Locally Advanced Intrahepatic Cholangiocarcinoma, Oligometastatic Intrahepatic Cholangiocarcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Intrahepatic Cholangiocarcinoma
Interventions
Angiography, Biopsy, Biospecimen Collection, Computed Tomography, Durvalumab, Magnetic Resonance Imaging, Positron Emission Tomography, Tremelimumab, Yttrium-90 Microsphere Radioembolization
Procedure · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 22, 2026, 9:32 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02446600
View directory record Official record
Conditions
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Tumor, Ovarian Seromucinous Carcinoma, Ovarian Serous Tumor, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Biospecimen Collection, Carboplatin, Cediranib Maleate, Computed Tomography, Echocardiography Test, Gemcitabine, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Pharmacological Study, Quality-of-Life Assessment
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
337
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 256 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 22, 2026, 9:32 PM EDT
Completed Phase 4 Interventional

18F-fluoride (18F-NaF) PET for Identifying Coronary Atherosclerotic Plaques

NCT02607748
View directory record Official record
Conditions
Coronary Artery Disease, Atherosclerotic Plaque
Interventions
18F-NaF PET and coronary CTA imaging
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2022 · Synced Oct 22, 2026, 9:32 PM EDT
Completed Phase 3 Interventional Results available

Gadobutrol Enhanced MRA of the Supra-aortic Vessels

NCT01344447
View directory record Official record
Conditions
Carotid Stenosis
Interventions
Gadobutrol (Gadovist, BAY86-4875)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
15
States / cities
Tucson, Arizona • Jacksonville, Florida • Savannah, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2019 · Synced Oct 22, 2026, 9:32 PM EDT
Recruiting No phase listed Observational

Effect of the Stellate Ganglion Block on the Retinal Microcirculation

NCT06797752
View directory record Official record
Conditions
OCTA, Severe Brain Injury, Subarachnoid Hemorrhage, Intracerebral Hemorrhage
Interventions
OCTA Scan
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Oct 22, 2026, 9:32 PM EDT
Completed Phase 2Phase 3 Interventional

Familiarization and Safety Study of PB127 Ultrasound Contrast Agent

NCT00594698
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PB127 for injectable suspension
Drug
Lead sponsor
Point Biomedical
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
34
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Long Beach, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2008 · Synced Oct 22, 2026, 9:32 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Using CTA Measures to Define Cardiac Risk In NFL Alumni

NCT06831409
View directory record Official record
Conditions
Coronary Artery Disease (CAD), Heart Disease, Coronary Atherosclerosis
Interventions
Coronary computed tomography angiography
Diagnostic Test
Lead sponsor
HeartFlow, Inc.
Industry
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Greenwood Village, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 22, 2026, 9:32 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

FDM for Subacute and Chronic Extremity Pain in the ED

NCT04555239
View directory record Official record
Conditions
Myofascial Pain, Chronic Pain, Extremities Disorders, Osteopathic Manipulation
Interventions
Fascial Distortion Model (FDM), Standard Care
Procedure · Other
Lead sponsor
Carilion Clinic
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
4
States / cities
Christiansburg, Virginia • Lexington, Virginia • Roanoke, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 22, 2026, 9:32 PM EDT
Recruiting Phase 2 Interventional

Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

NCT06815003
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Graft Versus Host Disease, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Echocardiography, Fludarabine, Melphalan, Multigated Acquisition Scan, Questionnaire Administration, Tacrolimus, Vedolizumab
Procedure · Drug · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 22, 2026, 9:32 PM EDT
Recruiting Phase 4 Interventional

Measuring the Effects of Netarsudil, Latanoprost, and Combination Therapy on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects

NCT04401982
View directory record Official record
Conditions
Ocular Hypertension, Suspect Glaucoma
Interventions
Rocklatan (Netarsudil 0.02%/ latanoprost 0.005), Latanoprost (0.005%)
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Baltimore, Maryland • Columbia, Maryland • Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 22, 2026, 9:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Breathing-Induced Myocardial Oxygenation Reserve

NCT03050346
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Other
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 7, 2022 · Synced Oct 22, 2026, 9:32 PM EDT
Recruiting Phase 3 Interventional

Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular Disease

NCT07348640
View directory record Official record
Conditions
Steno-occlusive Disease
Interventions
gadopiclenol, Gadoterate meglumine (Dotarem)
Drug
Lead sponsor
Guerbet
Industry
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
6
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 22, 2026, 9:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Distal Transradial Access for Percutaneous Coronary Intervention

NCT04801901
View directory record Official record
Conditions
Transradial Access, Coronary Angiography, Radial Artery Intimal Medial Thickness, Distal Radial Artery Access (dTRA)
Interventions
dTRA, fTRA
Procedure
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 15, 2022 · Synced Oct 22, 2026, 9:32 PM EDT
Recruiting Phase 2 Interventional

Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

NCT03970096
View directory record Official record
Conditions
Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
Interventions
Total-Body Irradiation, Thiotepa, Fludarabine, Tacrolimus, Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Methotrexate, Cyclophosphamide, Peripheral Blood Stem Cell, Cyclosporine, Sirolimus, Busulfan, Bone Marrow Aspiration and Biopsy, Echocardiography, Multigated Acquisition Scan, Biospecimen Collection
Radiation · Drug · Biological + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
1 Year to 60 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
3
States / cities
Tampa, Florida • Pittsburgh, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 22, 2026, 9:32 PM EDT
Recruiting Phase 1 Interventional

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

NCT06222580
View directory record Official record
Conditions
Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With KMT2A Rearrangement, Acute Myeloid Leukemia With NPM1 Mutation, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Gilteritinib, Revumenib, Echocardiography Test, Multigated Acquisition Scan
Procedure · Drug
Lead sponsor
Uma Borate
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Chapel Hill, North Carolina • Columbus, Ohio • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 22, 2026, 9:32 PM EDT
Completed Phase 4 Interventional Results available

Effects of Sublingual and Transdermal Administration of Nitroglycerin for Coronary CT Angiography on Image Quality

NCT02961946
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Nitroglycerin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 22, 2026, 9:32 PM EDT
Terminated No phase listed Observational

Non-Contrast Magnetic Resonance Angiography Assessment of Patients Referred for Transcatheter Aortic Valve Implantation

NCT02007967
View directory record Official record
Conditions
Aortic Valve Stenosis
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 22, 2016 · Synced Oct 22, 2026, 9:32 PM EDT
Recruiting Phase 2Phase 3 Interventional

Remote Ischemic Preconditioning for Renal and Cardiac Protection in Congestive Heart Failure (RICH) Trial

NCT04982419
View directory record Official record
Conditions
Acute Kidney Injury, Heart Failure, Contrast Induced Nephropathy, Coronary Angiography, Percutaneous Coronary Intervention
Interventions
Remote ischemic preconditioning, Sham remote ischemic conditioning
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania • Dallas, Texas • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 22, 2026, 9:32 PM EDT
Terminated No phase listed Observational

Short-term Perfusion Angiography Pilot Study (SPA)

NCT03054636
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Not listed
Lead sponsor
Volcano Corporation
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
4
States / cities
Miami, Florida • Wyoming, Michigan • Raleigh, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2020 · Synced Oct 22, 2026, 9:32 PM EDT
Terminated Phase 2 Interventional Results available

MT1002 Phase II Study in ACS Patients With PCI

NCT04723186
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
MT1002 for Injection
Drug
Lead sponsor
Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Industry
Eligibility
18 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Muncie, Indiana
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 22, 2026, 9:32 PM EDT